Viking Therapeutics Emerges as Major Contender in Weight-Loss Drug Arena
Published on 11/10/2025 at 14:01 | Redaktion boerse-global.de
Viking Therapeutics has captured significant market attention following the release of impressive clinical trial results for its obesity treatment candidate VK2735. The biopharmaceutical company’s latest data positions it as a serious competitor in the rapidly expanding metabolic health market.
Market observers are closely watching Viking Therapeutics’ scheduled appearances at two major November 2025 healthcare conferences: the Stifel 2025 Healthcare Conference and the Jefferies 2025 Global Healthcare Conference in London. These events are expected to provide additional momentum for the company’s visibility among investors.
The investment community has already taken notice of Viking’s progress. Roberts Glore & Co. has established a new position in the company, while William Blair analysts Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
